Not Yet RecruitingPhase 1LSD
Shortened LSD Intervention for Major Depressive Disorder
Sponsored by Johns Hopkins University
NCT ID
NCT07503002
Target Enrollment
10 participants
Start Date
2026-07-01
Est. Completion
2027-12-01
About This Study
The purpose of this study is to determine the safety and clinical effectiveness of a shortened lysergic acid diethylamide (LSD) experience. This will be achieved by administering the drug risperidone 45-minutes after the administration of LSD.
Conditions Studied
Interventions
- •LSD
- •Risperidone
Eligibility
Age:21 Years - 70 Years
Healthy Volunteers:No
View full eligibility criteria
Inclusion Criteria: * Have given written informed consent * Meet DSM-5 criteria for MDD * MADRS \>= 28 at screening Can read, write, and speak English fluently * Be judged by study team clinicians to be at low risk for suicidality Exclusion Criteria: * Women who are pregnant, nursing, or not practicing an effective means of birth control * Cardiovascular conditions: hypertension with resting blood pressure systolic \>139 or diastolic \>89, angina, heart rate \> 99, a clinically significant ECG abnormality (e.g., atrial fibrillation, QTc \> 450), TIA in the last 6 months stroke, peripheral or pulmonary vascular disease, cardiac valvulopathy * Epilepsy * Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia * Currently taking antipsychotics, or MAO inhibitors * Patients taking antidepressant medications and unable to taper * Moderate or strong CYP2D6 inhibitor antidepressants must undergo a washout period of 4 weeks or five half-lives prior to treatment * Currently taking CYP2D6 inhibitor other than an antidepressant that will be tapered * Currently taking efavirenz, Acetaldehyde dehydrogenase inhibitors such as disulfiram (Antabuse), Alcohol dehydrogenase inhibitors, or UGT1A9 inhibitors or UGT1A10 inhibitors such as phenytoin, regorafenib, eltrombopag * Have a seizure disorder, multiple sclerosis, history of significant head trauma, CNS tumor, movement disorders or any neurodegenerative condition * Morbidly obese (\>100 lbs. above ideal body weight, or BMI \>=40, or BMI \>=35 with high blood pressure or diabetes) * Be judged by a study team clinician to be at risk for moderate or severe alcohol or benzodiazepine withdrawal * Body weight \< 45 kg * Significant acute adverse reaction (e.g., dystonia) to an antipsychotic * Current or past history of meeting DSM-5 criteria for Schizophrenia, Psychotic Disorder (including substance-induced), Bipolar I or II Disorder or Major * Depression with psychotic features * Have a first degree relative with schizophrenia, psychotic disorder (unless substance induced or due to a medical condition), or Bipolar I Disorder.
Study Locations (1)
Johns Hopkins Center for Psychedelic and Consciousness Research
Baltimore, Maryland, United States